XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has partnered with a German diagnostics firm to become a leader in commercializing breakthrough tech in rapid, definitive testing for COVID-19 in strategic and convenient point-of-care (“POC”) settings. A recent article noted that, using standard polymerase chain reaction (“PCR”) equipment, XPhyto has the ability to significantly speed up testing for COVID-19. The equipment is commonly found in most analytical laboratories as well as hospitals and a range of POC settings. The announcement was based on the successful trial validation results of XPhyto’s proprietary rapid PCR test kit, developed in collaboration with Stuttgard-based 3a-Diagnostics GmbH. The company plans on initially applying for regulatory approval in Germany while also preparing for a commercial launch of its product early this year. The article reported that faster definitive diagnostic processes were especially urgent as the go-to rapid antigen testing has fallen out of favor; the article also called PCR the gold standard for coronavirus testing because of its reliability for generating accurate results. “XPhyto’s announcement attests to the completion of successful validation trials, which demonstrated diagnostic-level sensitivity and specificity for the test kit,” the article stated. “However, it is not the high degree of accuracy that really sets the test apart; instead, it is the ability to shorten testing turnaround times from at least a few hours to as little as 25 minutes. . . .XPhyto’s kit only requires a single PCR cycle which is complete in 20 minutes, while most PCR test systems require at least an hour — and sometimes several — to complete a mult-step viral RNA amplification process. XPhyto’s test kit also requires significantly less non-PCR laboratory processing time, including labour. Furthermore, it employs reagents that are readily available.”
For more information, visit https://ibn.fm/ewmKo
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
